Acquavella John, Mehra Reena, Bron Morgan, Suomi Joanna M-H, Hess Gregory P
Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Neurologic Institute, Cleveland Clinic, Cleveland, Ohio.
J Clin Sleep Med. 2020 Aug 15;16(8):1255-1263. doi: 10.5664/jcsm.8482.
The primary objective was to describe trends in the 2-year limited duration prevalence of narcolepsy from 2013-2016 in a large insured population with claims activity. Secondary objectives were to assess the prevalence of other sleep disorders and the frequency of diagnostic sleep testing.
Nationwide medical/prescription claims (Symphony Health) were analyzed to estimate the annual prevalence per 100,000 persons of narcolepsy and other sleep disorders (obstructive sleep apnea, idiopathic hypersomnia, rapid eye movement sleep behavior disorder, periodic limb movement disorder) and the frequency of diagnostic sleep testing. Prevalence was adjusted to the age/sex distribution of the 2016 US census estimates.
The prevalence of narcolepsy per 100,000 persons increased 14% from 38.9 in 2013 to 44.3 in 2016. Obstructive sleep apnea prevalence increased 41% over the study period from 2,429 to 3,420 per 100,000. Large increases in prevalence were also seen for idiopathic hypersomnia (32%), periodic limb movement disorder (30%), and rapid eye movement sleep behavior disorder (64%). For each sleep disorder, prevalence was higher for those with commercial insurance versus Medicare/Medicaid, and markedly lower prevalence was observed for the Northeast compared with the Midwest, South, and Western US regions. The frequency of multiple sleep latency/maintenance of wakefulness testing declined by 20%, and polysomnography declined by 15%. Conversely, home sleep apnea testing increased by 117%.
The prevalence of narcolepsy, obstructive sleep apnea, and the other sleep disorders increased appreciably over the 2013-2016 period. It remains to be determined whether the trends seen in our analyses are due to increased incidence or increased awareness of these conditions.
主要目的是描述2013年至2016年期间,在有理赔活动的大量参保人群中发作性睡病的2年有限期患病率趋势。次要目的是评估其他睡眠障碍的患病率以及诊断性睡眠测试的频率。
分析全国范围内的医疗/处方理赔数据(Symphony Health),以估算每10万人中发作性睡病及其他睡眠障碍(阻塞性睡眠呼吸暂停、特发性嗜睡症、快速眼动睡眠行为障碍、周期性肢体运动障碍)的年患病率以及诊断性睡眠测试的频率。患病率根据2016年美国人口普查估计的年龄/性别分布进行了调整。
每10万人中发作性睡病的患病率从2013年的38.9上升至2016年的44.3,增长了14%。在研究期间,阻塞性睡眠呼吸暂停的患病率从每10万人2429例增加到3420例,增长了41%。特发性嗜睡症(32%)、周期性肢体运动障碍(30%)和快速眼动睡眠行为障碍(64%)的患病率也有大幅上升。对于每种睡眠障碍,商业保险人群的患病率高于医疗保险/医疗补助人群,与美国中西部、南部和西部地区相比,东北部地区的患病率明显较低。多次睡眠潜伏期/清醒维持测试的频率下降了20%,多导睡眠图测试下降了15%。相反,家庭睡眠呼吸暂停测试增加了117%。
在2013年至2016年期间,发作性睡病、阻塞性睡眠呼吸暂停及其他睡眠障碍的患病率显著上升。我们分析中观察到的这些趋势是由于发病率增加还是对这些疾病的认识提高,仍有待确定。